Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
52 /100
HIGH RISK
Score updated Oct 27, 2026

PACB — Pacific Biosciences of California, Inc. Dilution Risk Tracker

Track PACB dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track PACB — Get alerts when the score changes →

As of October 27, 2026, Pacific Biosciences of California, Inc. (PACB) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Pacific Biosciences of California, Inc. has a market capitalization of $742.89M, 310.83M shares outstanding, 235 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
65
📊 Float Risk
22
⚠️ Warrant Exposure
40
🔄 Convertible Debt
85

Dilution Forecast

⛈️
Warning
High probability of dilution event
model est. 45%
🔁 Convertible Conversion model 60%
• Major convertible overhang: 87% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split model est. 40%
• 50-day avg $1.43 approaching $1 threshold
• 11 months cash with weak price
💰 Capital Raise model 15%
• Under 12 months cash (11mo)
🔔 Track PACB — Get forecast alerts →

Market Data

Market Cap$742.89M
Shares Outstanding310.83M
Float303.44M
Cash$236.87M
Debt$13.53M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore52/100DilutionWatch score record
Shares Outstanding310.83MVerified float table or market cache
Public Float303.44MVerified float table or market cache
Market Cap$742.89MMarket data cache
Cash Runway11.0 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 3 1, 4 4, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

PACB SEC Filing Activity — Last 12 Months

Shares outstanding reported by PACB on the cover page of its latest 10-K/10-Q: 310.83M as of July 31, 2026.

DilutionWatch recorded no shelf, registration or prospectus documents for PACB in the last 12 months. Full filing list on SEC EDGAR →

FormWhat it isFilingsMost recent
8-Kcurrent report (material event)3Jul 09, 2026
10-Qquarterly report2Aug 06, 2026
DEF 14Aproxy statement1Apr 23, 2026
SC 13G/Aamended passive >5% holder filing1Aug 14, 2026
3initial insider ownership23Oct 08, 2026

Institutional Holdings

QoQ: ↑ 4.8% shares (2026Q1 vs prior)
235 institutional holders · 217.52M shares
#1 ARK Investment Management LLC 36.27M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 25.55M shares
#3 BlackRock, Inc. 25.27M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest46.93M
Days to Cover2.2
% of Float15.5%
FINRA data as of Oct 15, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-08-06
4 INSIDER TRANSACTION 2026-03-05
3 FORM3 2026-03-05
4 INSIDER TRANSACTION 2026-03-04
4 INSIDER TRANSACTION 2026-03-04
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual PACB Dilution Snapshot

Pacific Biosciences of California, Inc. (PACB) has a DilutionScore of 52/100, rated High dilution risk. Score date: October 27, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

PACB's DilutionScore is currently 52/100 (High risk), with 2 score changes tracked over 89 days. The score improved from 36/100 (Medium risk).

Period Score Risk Level Duration
Aug 22 – Oct 27, 202652/100HIGH67 days
Aug 14 – Aug 21, 202636/100MEDIUM7 days
Jul 30 – Aug 13, 202641/100MEDIUM15 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

PACB shares outstanding have increased 2.8% from 302.00M (Mar 2026) to 310.60M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 23, 2026310.60M303.44M▲ 0.36%
May 12, 2026310.60M302.35M▲ 1.56%
May 10, 2026310.49M297.69M▲ 1.27%
May 03, 2026310.49M293.97M▲ 0.08%
Apr 07, 2026302.00M293.75M▼ 0.42%
Mar 19, 2026302.00M294.99M▼ 0.04%
Mar 15, 2026302.00M295.12M▲ 0.80%
Mar 09, 2026302.00M292.79M▼ 0.87%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track PACB Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment PACB files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking PACB — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,566+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for PACB
PACB FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.